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Abstract
Background: Evidence regarding prevalence of COVID-19 related Olfactory dysfunction (OD) 
among ambulatory patients is highly variable due to heterogeneity in study population and 
measurement methods. Relatively few studies have longitudinally investigated OD in ambulatory 
patients with objective methods.
Methods: We performed a longitudinal study to investigate OD among COVID-19 ambulatory 
patients compared to symptomatic controls who test negative. Out of 81 patients enrolled, 45 
COVID-19 positive patients and an age- and sex-matched symptomatic control group completed 
the BSIT and a questionnaire about smell, taste and nasal symptoms. These were repeated at 
1 month for all COVID-19 positive patients, and again at 3 months for those who exhibited 
persistent OD. Analysis was performed by mixed-effects linear and logistic regression.
Results: 46.7% of COVID-19 patients compared to 3.8% of symptomatic controls exhibited OD 
at 1-week post diagnosis (p<0.001). At 1 month, 16.7%, (6 of 36), of COVID-19 patients had 
persistent OD. Mean improvement in BSIT score in COVID-19 patients between 1-week BSIT 
and 1 month follow-up was 2.0 (95% CI 1.00 – 3.00, p<0.001). OD did not correlate with nasal 
congestion (r= −0.25, 95% CI, −0.52 to 0.06, p=0.12).
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Conclusions: Ambulatory COVID-19 patients exhibited OD significantly more frequently than 
symptomatic controls. Most patients regained normal olfaction by 1 month. The BSIT is a simple 
validated and objective test to investigate the prevalence of OD in ambulatory patients. OD did not 
correlate with nasal congestion which suggests a congestion-independent mechanism of OD.
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INTRODUCTION
SARS-CoV-2 has become ubiquitous throughout the world, infecting more than 130 million 
people, and prompting the largest public health intervention in history.(1) Many containment 
strategies rely on early identification and isolation of infected individuals. In this regard, 
COVID-19 related olfactory dysfunction (OD), having been identified as an early indicator 
of infection by the World Health Organization (WHO) and Center for Disease Control and 
Prevention (CDC),(2,3) represents a red flag that could help clinicians, public health officials 
and the general public contain the spread of disease.(4)
A recent meta-analysis of nearly 30,000 patients reported a prevalence of COVID-19 related 
OD of 47.9% (95% confidence interval [CI]: 41.2 – 54.5).(5) Notably, further systemic 
review has revealed a wide range in reported prevalence (19 – 73.6%),(6) and furthermore 
prevalence was higher among studies using objective methods (72.1% vs 44.5%).(5) Lima 
et al and Prajapati et al have independently found that 30–40% of patients with objectively 
measured OD may not actually perceive OD by self-report.(7,8) Furthermore, significant 
heterogeneity (I2: >90%) exists, not only between measurement methods, but also between 
study populations which has limited precise definition of prevalence.(5) However, Moein 
et al. report near universal prevalence of OD (96%) among hospitalized patients using 
objective psychophysical testing.(9)
While knowledge of OD in hospitalized patients is important, understanding its 
manifestations in ambulatory patients bears more relevance to the pandemic response. This 
is especially true as these patients are in the community, have milder symptoms or are 
otherwise asymptomatic, and thus may not isolate themselves to prevent transmission. The 
reported prevalence of COVID-19 related OD among ambulatory patients has significant 
variation, which is in part attributable to differing measurement methods: 41.1%(10) (Lee 
et al. survey), 66.3(11) (Boscolo-Rizzo et al. survey) 68%(12) (Yan et al. survey), 70%(13) 
(Niklassen et al. objective threshold testing). Evidence regarding resolution of OD in 
ambulatory patients is mainly from survey data, though some have used threshold and 
psychophysical testing.(13–16) In a predominately outpatient cohort, Gorzkowski et al. used 
a survey to find that greater than 95% of COVID-19 patients reported improvement in 
olfaction by 26 days after onset, and the mean time from onset to start of recovery was 
11.6 days.(17) Studies using threshold testing identified OD in 27% to 37% of patients 1–5 
months after onset.(13,14)
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This is a prospective longitudinal cohort study using the Brief Smell Identification Test 
(BSIT) in ambulatory patients with COVID-19 compared to symptomatic controls. Its 
findings contribute to the growing body of objectively measured olfactory literature 
regarding prevalence and recovery of COVID-19 related OD among ambulatory patients. 
Additionally, this study contributes to prognostic clarity for patients suffering from 
COVID-19 related OD.
MATERIALS AND METHODS
Study Design and Patient Population
This study was approved by the Institutional Review Board at UNC (IRB# 20-1992). The 
schedule of events is depicted in Figure 1. Patients presenting to a respiratory diagnostic 
center (RDC) affiliated with the University of North Carolina (UNC) Health system were 
prospectively enrolled in a longitudinal study. Patients were enrolled between August 3, 
2020 and November 19, 2020 within 1–5 days of a SARS-CoV-2 polymerase chain reaction 
(PCR) test. Inclusion criteria included: age ≥ 18 years and presentation to a UNC RDC. 
Exclusion criteria included: hospitalization, presence of OD at baseline, or non-English 
speaking. Asymptomatic patients were excluded from the COVID-19 negative control group. 
The control group was age- and sex-matched (+/− 3 years).
Participants were enrolled during a phone encounter 1–5 days after diagnosis at which point, 
they were specifically asked about smell loss, and were administered a past medical history 
questionnaire. One week after a COVID-19 test, participants were provided an enrollment 
packet including a 12-item Brief Smell Identification Test (BSIT), and a symptom 
questionnaire inquiring about nasal, olfactory and gustatory symptoms (Supplemental File). 
All COVID-19 positive patients were sent a follow-up BSIT and symptom questionnaire 
1 month after their positive test. COVID-19 positive patients who exhibited OD received 
an additional BSIT and symptom questionnaire 3 months after their positive test. The 
age and sex matched control group all presented to a testing center with symptoms of 
COVID-19 but had a negative SARS-CoV-2 PCR test. They completed the BSIT and 
symptom questionnaire only at 1-week post diagnosis.
Olfactory Testing and Questionnaire
The BSIT is a 12-item psychophysical olfactory test that is validated with good test-retest 
reliability (Sensonics International, Haddon Heights, NJ). Each correctly identified odorant 
from a list of four multiple choice options confers one point. The BSIT has a minimal 
clinically important difference (MCID) of 1 question.(18) A score <9 indicates OD.(19) A 
score <4 fails to surpass guesswork which may suggest complete anosmia. A score <2 is 
suggestive of malingering. Nasal, olfactory, and gustatory symptoms were assessed using a 
13-question survey on a 5-point Likert scale. The olfactory and gustatory questions were 
derived from a validated chemosensory questionnaire for patients treated for head and neck 
cancer. (20) Three additional questions were included regarding nasal symptoms such as 
congestion, pain and drainage. The Likert scale assessed frequency of symptoms, ranging 
from 1=never, 2=rarely, 3=sometimes, 4=often, to 5=always.
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Baseline demographics, presenting symptoms and comorbid conditions were obtained by 
combination of a pre-specified telephone questionnaire and medical record review. The 
selection of comorbid conditions was taken directly from the CDC list of high-risk 
conditions for COVID-19.(21) The telephone questionnaire also asked about history of 
conditions that have potential to impair olfaction at baseline, such as head injury, sinus 
surgery, or allergic rhinitis.
Statistical Analysis
Statistical analysis was performed by GraphPad Prism version 9 (GraphPad Software, La 
Jolla, CA) and SAS version 9.4 (Cary, NC). Descriptive statistics were used to report 
baseline characteristics, clinical features and comorbid conditions. These were reported as 
means, percentages, standard deviation (SD), ranges and absolute numbers.
The primary outcomes were the percentage of COVID-19 positive patients with OD at 
1-week compared to their matched control group as well as to percentage of COVID-19 
positive patients exhibiting persistent OD at 1 month follow-up. Statistical significance was 
set at p < 0.05.
A linear mixed-effects model was used to compare 1-week BSIT scores as continuous 
variables between the COVID-19 positive group and controls. Fixed effects included time 
and group, and time by group interaction. A random subject effect was included. The same 
model was also used to compare the 1-week BSIT in the COVID-19 group to BSIT at 
1-month post diagnosis. A mixed effects logistic regression was used to make the same 
comparisons with OD as a categorical variable (BSIT <9 represents measurable OD).
Pearson correlation and simple linear regression was performed to assess the relationship 
between nasal congestion and BSIT scores in the COVID-19 positive group at 1-week. 
Simple linear regression was used to validate a subjective olfactory composite score derived 
from the symptoms questionnaire in predicting OD as measured by BSIT.
RESULTS
81 ambulatory patients with SARS-CoV-2 positive PCR tests and 38 symptomatic but 
SARS-CoV-2 PCR negative controls were enrolled. Of the enrolled patients, 45 COVID-19 
positive patients completed the 1-week BSIT and questionnaire and 36 participants 
completed a 1-month BSIT. 5 participants who had persistent smell loss at 1 month were 
sent a 3 month follow up BSIT, and 3 of these 5 participants completed the test. 26 
symptomatic controls who presented to a RDC but were SARS-CoV-2 PCR test negative, 
completed a 1-week BSIT and symptom questionnaire. These results as well as baseline 
demographics, comorbidities and clinical characteristics are shown in Table 1. Figure 1 
depicts the schedule of events. Despite significant attrition, patients completing a BSIT 
reported very similar rates of smell loss at the time of phone encounter compared to the total 
enrollment (57.4 vs 57.1%; p>0.999, figure 1).
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Comparison of 1-Week BSIT Scores in COVID-19 Positive Patients vs Symptomatic 
Controls
In the COVID-19 positive cohort, the mean time between COVID-19 test and 1 week time 
point for BSIT completion was 8.9 days (95% CI 7.4–10.4) compared to 8.2 days (95% 
CI 7.1–9.2) in the control cohort. At 1 week, 46.7% (21 of 45) of COVID-19 participants 
had measurable OD (BSIT<9) compared to 3.8% (1 of 26) of controls (p<0.001). The mean 
BSIT score at 1-week in the COVID-19 group was 7.9 out of a total of 12 (95% CI 7.1 – 
8.6) compared to 10.7 (95% CI 9.7 – 11.7) in the control group, resulting in a difference 
of −2.9 (95% CI −4.1 to −1.6, p<0.001; Figure 2, panel A). As above, previous studies 
have validated a minimal clinically important difference of 1.0.(18) There were no significant 
differences in sinonasal symptom burden, including frequency of nasal pain, drainage, or 
congestion, between COVID-19 patients and symptomatic controls (Figure S1).
Stratified BSIT scores among COVID-19 patients and symptomatic controls are shown in 
figure 2, panel B. Among COVID-19 patients who did exhibit OD (n=21), 28.6%, (n=6) 
demonstrated scores in the lowest quartile, (0–3). An additional 38.0% (n=8) had slightly 
better scores (4–6), and 33.3% (n=7) of patients demonstrated mild OD (7–8). The only 
patient in the control cohort who exhibited OD had a BSIT score of 8.
Longitudinal Olfactory Outcome
In the COVID-19 positive cohort, the mean time between the COVID-19 test date and 
follow-up BSIT completion was 38.4 days (95% CI 35.6–41.1: Figure 3, Panel B). At 
follow-up, 16.7% (6 of 36) in the COVID-19 cohort had persistent OD. The follow-up BSIT 
in COVID-19 patients improved by a clinically significant 2.0 (95% CI 1.0 – 3.0, p<0.001; 
Figure 3, Panel A), from 7.9 (95% CI 7.1 – 8.6) to 9.9 (95% CI 9.0 –10.7).
Questionnaire and Self-reported Nasal Congestion
Results of the questionnaire, which can be found in the supplementary file, demonstrated 
significant differences in smell and taste related symptoms, and notably there were no 
significant differences in nasal symptoms between COVID-19 group and symptomatic 
controls (Figures S1–S6). COVID-19 positive patients exhibited no correlation between the 
1-week BSIT and the frequency of patient reported nasal congestion (r=−0.233, p=0.13; 
slope = −0.638, 95% CI −1.48 to 0.203; Figure 4, Panel A). Furthermore, there was 
no significant difference between the frequency of self-reported congestion in COVID-19 
patients compared to controls, while there was a significant difference in self-reported 
difficulty with smell (1.65, p<0.0001; Figure 4, Panel B).
DISCUSSION
This study prospectively compared olfactory function between ambulatory patients with 
COVID-19 and symptomatic controls who tested negative. Additionally, we longitudinally 
followed the COVID-19 positive cohort for 3 months to assess recovery of olfaction.
This study used objective psychophysical testing to investigate the incidence of COVID-19 
related OD in ambulatory patients compared to symptomatic patients who test negative 
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(46.7% vs. 3.8%, p<0.001). Stratified BSIT scores revealed that about one-third of patients 
with olfactory dysfunction had complete anosmia (score 0–3), and about two-thirds were 
confined to the lower 2 quartiles of olfactory scores (scores 0–6; Figure 2, Panel B).
Our longitudinal findings indicate that a great majority of COVID-19 ambulatory patients 
will recover normal olfaction after 1 month (83.3%), and this may be underestimated due 
to attrition. Recovery of olfaction may represent the clinical consequence of the basic 
pathophysiologic mechanism of COVID-19-related OD, which is thought to be secondary 
to SARS-CoV-2 infection of the supporting sustentacular cells, which express ACE2 and 
TMPRSS2, and not the olfactory neurons directly.(22) This mechanism may also explain 
why we did not find any correlation between BSIT scores and the frequency of nasal 
congestion; whereas many other pathogens cause transient OD by mechanical obstruction 
of the olfactory cleft through nasal congestion. Our results clinically support the basic 
hypothesis that SARS-CoV-2 causes OD independent of nasal congestion (Figure 4).
This study has several limitations. Firstly, it would be ideal to obtain olfactory testing earlier 
and more frequently following COVID-19 diagnosis. This potentially could have identified 
patients who had OD but recovered prior to their first BSIT; this also would have more 
precisely delineated the natural history of OD.
Additionally, there is risk for selection bias for study entry and selection bias by attrition, 
as patients with smell loss may be more interested in participating than patients without 
chemosensory complaints. However, this appears to be minimal given similar baseline 
characteristics between patients who enrolled, and those who were lost to follow-up; most 
importantly, the rates of self-reported OD at the time of phone encounter in COVID-19 
positive patients who completed a BSIT compared to the entire enrollment were very 
similar, (57.4% vs 57.1%; p>0.999, Figure 1).
CONCLUSIONS
The precise rate of OD among ambulatory patients with COVID-19 is unknown. Incidence 
of OD is significantly higher than in patients with similar symptoms who test negative for 
COVID-19. Although our study was not designed to correlate temporality between the onset 
of OD and infectivity, it is reasonable from these findings to advise ambulatory patients 
with new onset OD to quarantine and be tested for COVID-19. Additionally, this study 
provides further prognostic clarity for clinicians to be used in counseling patients that the 
great majority of ambulatory patients who experience COVID-19 related OD recover during 
the first month after diagnosis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Schedule of Events for COVID-19 Positive and Symptomatic Control Group. Patients were 
enrolled by phone encounter and were asked about smell loss 1–5 days after a SARS-CoV-2 
test. A cohort of COVID-19 patients and age- and sex-matched symptomatic controls were 
sent a BSIT and questionnaire 1-week post-diagnosis. All COVID-19 positive patients were 
sent a BSIT and questionnaire at 1 month, and those with persistent olfactory dysfunction 
(OD) at 1 month (n=5), received a third BSIT and questionnaire at 3 months. The bar graph 
shows self-reported OD at the time of phone encounter for the total enrollment (57.4%) in 
red compared to those who ultimately completed a BSIT (57.1%) in blue suggesting patients 
who completed a BSIT were similar to those who did not at the time of phone encounter.
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COVID-19 Positive Patients Have Significantly Lower BSIT Scores than Symptomatic 
Controls. A) The mean BSIT score at 1-week in the COVID- 19 group (blue) was 7.9 (95% 
CI 7.1 – 8.6) compared to 10.7 (95% CI 9.7 – 11.7) in the control group (orange), resulting 
in a difference of −2.9 (95% CI −4.1 to −1.6, p<0.001). Each participant score is represented 
by a dot. Error bars represent 95% confidence intervals. B) The same BSIT scores are plot- 
ted as a percentage of the population. Among abnormal BSIT scores in the COVID-19 group 
(n=21), 28.6% (n=6) were in the lowest quartile (score of 0–3), with an additional 38.0% 
(n=8) in the second to lowest quartile (score of 4–6). An additional 33.3% (n=7) exhibited 
mild OD (score of 7–8).
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BSIT Score improved significantly in COVID-19 patients between 1 week and 1 month. A) 
BSIT Score improved by 2.0 (95% CI 1.0 – 3.0) from 7.9 (95% CI 7.1 – 8.6) to 9.9 (95% CI 
9.0 – 10.7) in COVID-19 patients at baseline (blue) compared to 1 month later (green). B) 
Shows improvement in BSIT score (y-axis) from baseline (blue) to one month (green) with 
days from COVID-19 test on the x-axis. A score <9 indicates OD. The average time between 
COVID-19 test and 1-week BSIT was 8.9 days (95% CI 7.4 – 10.4). The average time from 
COVID-19 test to follow-up BSIT was 38.4 days (95% CI 35.6 – 41.1).
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BSIT Scores do not correlate with congestion COVID-19 patients suggesting a congestion 
independent mechanism of OD. A) There was no significant correlation between BSIT 
scores in COVID-19 patients and self-reported nasal congestion (r=−0.233, p=0.13). The 
simple linear regression (solid line) is plotted with 95% confidence interval bands (dotted 
lines), (slope = −0.638, 95% CI –1.48 to 0.203). Simulated noise was performed to display 
overlapping points. B) There was no significant difference between self-reported congestion 
in COVID-19 patients vs symptomatic controls (0.137, p=0.66). COVID-19 patients had 
self-reported increased difficulty smelling (−1.65, p<0.001). Error bars represent 95% 
confidence intervals. The questionnaire used a 5-point Likert scale (1=never, 2=rarely, 
3=sometimes, 4=often, 5=always). Q2: I have had nasal congestion. Q7: It has been hard for 
me to smell.
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Table 1.
Baseline Demographics, Clinical Characteristics and Comorbidities
COVID-19 (+) 
Phone Encounter
COVID-19 (+) 1 
week
a







Sample size 81 45 36 38 26
Mean age, years (SD; 
range)
38.21 (19;18–81) 39.87 (18; 18–81) 39.68 (18; 18–70) 38.45 (15;18–71) 39.38 (14;19–71)
Sex 52F/29M 32F/13M 25F/11M 26F/12M 20F/6M
Race/Ethnicity, n (%)
 Black 7 (8.6) 2 (4.4) 2 (6.1) 1 (2.6) 0
 Caucasian 43 (53.1) 31 (68.9) 25 (69.4) 30 (78.9) 23 (88.5)
 Hispanic 8 (9.9) 3 (6.7) 2 (5.6) 1 (2.6) 1 (3.8)





39 (57.4) 24 (57.1) 15 (50) 1 (2.6) 1 (4)
Smoking history 10 (12.7) 4 (8.9) 5 (13.9) 2 (4.8) 0
Prior history of smell 
loss
c
7 (9.5) 5 (11) 3 (8.3) 5 (13.5) 5 (20)
Prior history of taste 
loss
c
6 (8.0) 4 (8.9) 3 (8.3) 4 (10.5) 4 (15.3)
Medical/Surgical 
History
Sinusitis 24 (29.6) 14 (31.8) 14 (38.9) 17 (44.7) 14 (53.8)
Allergic rhinitis 34 (42.0) 20 (44.4) 18 (50) 23 (60.5) 19 (73.1)
Head trauma 10 (12.3) 7 (15.5) 6 (16.7) 9 (23.6) 9 (34.6)
Nose trauma 3 (3.7) 1 (2.2) 1 (2.8) 3 (7.9) 2 (7.7)
Sinus Surgery 3 (3.7) 2 (4.4) 1 (2.8) 2 (5.3) 2 (7.7)
Hypertension 12 (14.8) 7 (15.5) 7 (19.4) 2 (5.3) 1 (3.8)
Diabetes 4 (4.9) 2 (4.4) 0 0 0
Cardiovascular disease 4 (4.9) 2 (4.4) 3 (8.3) 0 0
Asthma 8 (9.9) 4 (8.9) 4 (11.1) 2 (5.3) 2 (7.7)
COPD 2 (2.5) 2 (4.4) 0 0 0
Pulmonary fibrosis 0 0 0 1 (2.6) 0
Cystic fibrosis 0 0 0 0 0
Pregnancy 1 (1.2) 0 0 0 0
a
1-week sample size refers to the number of patients who completed a BSIT at 1-week.
b
Participants were asked at enrollment during phone encounter if they experienced smell loss at any point since the onset of symptoms.
c
Prior history of smell or taste loss was determined by telephone prior to enrollment. Smell loss had to be resolved prior to onset of acute 
symptoms, and any patient with baseline smell loss was excluded.
Values may not add to 100% due to sporadic missingness.
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COVID-19 = Coronavirus Disease 2019.
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